Publications by authors named "C L Perrinjaquet"
The past year has brought several innovations in medical oncology, opening up promising new options for many solid tumors, both localized and metastatic. Immunotherapy, a real spearhead of emerging therapies in metastatic diseases, is seeing its use extend to adjuvant and neoadjuvant modalities, particularly in colon and lung cancers. 2022 also sees a great deal of focus on targeted therapies, as well as on antibody-drug conjugates, which creates new standards in both breast and lung cancers.
View Article and Find Full Text PDF[2021 Oncology update].
Rev Med Suisse
February 2022
Article Synopsis
- Medical oncology specialists are continuing their research for new treatments to enhance life expectancy and quality of life for patients, despite the ongoing impact of COVID-19 on global health and the economy.
- In 2021, immunotherapy has been proven effective, either alone or combined with other treatments, across various cancer types.
- The focus this year includes new therapeutic strategies in lung, breast, melanoma, gynecological, digestive, urological, and ENT cancers.
Intravesical immunotherapy with Calmette-Guerin bacillus (BCG) have been used since decades for the treatment of non-muscle invasive bladder cancer and is a proof of principle that immunotherapy works for this malignancy. Since 2016, immune checkpoint inhibitors (ICI) demonstrated clinical benefits in locally advanced or metastatic bladder cancer, providing potentially durable tumor control in first line therapy or upon relapse after standard treatments. Ongoing clinical trials aim to demonstrate the efficiency of ICI for the treatment of localized disease.
View Article and Find Full Text PDF[2020 oncology update].
Rev Med Suisse
January 2021
Article Synopsis
- - The COVID-19 pandemic has significantly altered daily practices and habits in healthcare since early 2020.
- - In 2020, new therapeutic approaches and combinations have emerged, enhancing patient outcomes and quality of life in oncology.
- - The article highlights recent advances in cancer treatments across various tumor types, including lung, breast, digestive, gynecological, urological, and ENT cancers.
Background And Aims: The occurrence rate of adverse events (AEs) related to care among hospitalized oncology patients in Switzerland remains unknown. The primary objective of this study was to describe, for the first time, the occurrence rate, type, severity of harm, and preventability of AEs related to care, reported in health records of hospitalized hematological and solid-tumor cancer patients in three Swiss hospitals.
Methods: Using an adapted version of the validated Global Trigger Tool (GTT) from the Institute for Healthcare Improvement, we conducted a retrospective record review of patients discharged from oncology units over a 6-week period during 2018.